Senti Biosciences news
- Business combination with Dynamics Special Purpose Corp. completed today; gross proceeds from transaction to Senti Bio expected to total approximately $156.5 million -
- Combined company Senti Bio will be listed on the Nasdaq Global Market under ticker symbol "SNTI" -
- IND filings for preclinical oncology candidates SENTI-202 and SENTI-301 anticipated in 2023 -
Senti Biosciences, Inc. (“Senti Bio”), a biotechnology
Senti Biosciences, Inc. (Senti Bio), a leading gene circuit company, today announced the appointment of Kanya Rajangam, MD, PhD, as Chief Medical and Development Officer. Dr. Rajangam, who will join the company this July, is an experienced biotechnology executive with an extensive track record of successfully developing cancer therapies across multiple modalities.
Senti Bio is developing next-generation cell and gene therapies engineered with gene circuits, which are designed to repro
- SENTI-202 oral presentation details systematic optimization of Logic Gating Gene Circuit technology in allogeneic CAR-NK cells to more precisely target tumor cells in acute myeloid leukemia, while sparing healthy cells
- SENTI-301 poster presentation highlights optimization of Multi-Arming and Regulator Dial Gene Circuits to improve the cytotoxicity of allogeneic CAR-NK cells and immune stimulation in hepatocellular carcinoma
- Smart Sensor G
- Three ASGCT abstracts highlight new data related to application of gene circuit technology to enhance efficacy and safety of cancer-killing CAR-NK cells
- ISCT abstract describes scalable, reproducible, cGMP-ready CAR-NK manufacturing process to support planned clinical development of oncology pipeline candidates
Senti Bio, a leading gene circuit company, today announced the acceptance of four abstracts for presentation at upcoming scientific c
Senti Biosciences, Inc. (“Senti Bio”), a leading Gene Circuit company today announced that co-founders Tim Lu, MD, PhD, Chief Executive Officer, and Philip Lee, PhD, Chief Technology Officer, will participate in a Fireside Chat at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 25, 2022 at 3:00 p.m. ET.
Senti Bio uses its Gene Circuit platform to progr
- Preclinical data demonstrate the use of gene circuits to improve the therapeutic potential of allogeneic CAR-NK cells for the treatment of solid tumors
- CAR-NK cells armed with calibrated release IL-15 achieve optimal cytokine distribution and result in superior killing and persistence
Senti Bio, a leading gene circuit company, today announced new data from preclinical studies that further demonstrates the Company`s ability to arm
Senti Bio, a leading gene circuit company, today announced the acceptance of an abstract for presentation at the American Association for Cancer Research (AACR) annual meeting in New Orleans taking place April 8–13, 2022.
The abstract, titled “Driving anti-tumor activity in solid tumors with controlled arming of allogeneic CAR-NK cells,” details the Company’s efforts to develop gene circuits to arm chimeric antigen receptor natural killer (CAR-NK) cells with mu
Senti Biosciences, Inc. (“Senti Bio”), a leading Gene Circuit company today announced that Tim Lu, MD, PhD, Chief Executive Officer and Co-Founder, will present a corporate overview at the 40th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, January 11, 2022 at 2:00 p.m. EST.
Senti Bio uses its Gene Circuit platform to program cell and gene therapies with potentially enhanced capabilit